Nutcracker Therapeutics Raises $167 Million in Series C Financing to Advance its mRNA Therapeutics and First-of-its-Kind Biochip-based Manufacturing Platform

EMERYVILLE, Calif.--(BUSINESS WIRE)--Significant financing round enables accelerated development of therapeutic pipeline built upon its proprietary RNA technology platform.

Click to view original post